Stocks and Investing
Stocks and Investing
Thu, March 2, 2017
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Joseph Schwartz Upgraded (SRPT) to Buy and Increased Target to $47 on, Mar 2nd, 2017
Joseph Schwartz of Leerink Swann, Upgraded "Sarepta Therapeutics, Inc." (SRPT) to Buy and Increased Target from $27 to $47 on, Mar 2nd, 2017.
Joseph has made no other calls on SRPT in the last 4 months.
There is 1 other peer that has a rating on SRPT. Out of the 1 peers that are also analyzing SRPT, 0 agree with Joseph's Rating of Hold.
This is the rating of the analyst that currently disagrees with Joseph
- Anupam Rama of "JP Morgan" Initiated at Buy and Held Target at $40 on, Thursday, December 22nd, 2016
Contributing Sources